Medical insurance has covered it! Capmatinib Medication Guide and Real Efficacy Revealed

1. Breaking News:METThe domestic launch of the mutation-targeted drug capmatinib has attracted attention

At the end of 2024, a piece of news about"Capmatinib (Capmatinib) was officially included in medical insurance" quickly appeared on the hot lists of many medical media. This incident not only marks an important breakthrough in the field of MET mutated non-small cell lung cancer (NSCLC) in China, but also gives new hope to countless patients troubled by MET gene mutations.

In the era of targeted therapy, EGFR, ALK, ROS1, RET are relatively mature, but METexon14 skipping mutations (METex14 Skipping) patients have been in the dilemma of lack of effective treatment for a long time. The emergence of capmatinib broke this situation.

As the world's first targeted drug approved for the treatment of MET mutated lung cancer, the inclusion of capmatinib in medical insurance is undoubtedly a hot event in the field of oncology.

2. Drug overview: What is capmatinib?

Capmatinib (Capmatinib, trade name: Tabrecta) was developed by Novartis (Novartis) and is a highly selective MET inhibitor. Its main mechanism of action is to block the signal transduction of MET receptor tyrosine kinase (MET-TKI), thereby inhibiting the proliferation, migration and invasion of tumor cells.

MET gene mutations can cause abnormal activity of cancer cells and promote tumor growth and metastasis. Capmatinib can precisely target this mutation, causing cancer cells to "lose their drive" and inhibit tumor development from the source.

Compared with traditional chemotherapy, capmatinib has the following significant advantages:

1.Oral administration, easy to use;

2.Low toxicity and mild side effects;

3.The efficacy is stable and the onset of effect is rapid;

4.Can effectively control brain metastases.

3. Clinical research data of capmatinib

The clinical efficacy of capmatinib has been confirmed by a number of international authoritative trials, the most representative of which is the GEOMETRY mono-1 study.

Research results show:

In untreated METex14mutated NSCLC patients, capmatinib’s objective response rate (ORR) was as high as 68%;

Among patients who had previously received chemotherapy, ORR still reached 41%;

The duration of efficacy (DOR) can reach 12.6 months;

The intracranial remission rate in patients with brain metastases exceeds50%, significantly improving the quality of life.

This means that capmatinib is not only effective against lung lesions, but also has a significant control effect on refractory areas such as brain metastases.

The United StatesFDA approved capmatinib as early as 2020 based on this study for the treatment of MET mutated non-small cell lung cancer, and was subsequently launched in the European Union, Japan, Singapore and other places.

4. Indications and Medication Guide

1.Indications:

Capmatinib is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying METexon14 skipping mutation (METex14 skipping mutation).

2.Usage and dosage:

Recommended dose: 400mg, taken orally twice a day (taken in the morning and evening).

During medication, avoid taking strongCYP3A4 inhibitors or inducers at the same time to avoid affecting the efficacy of the drug.

The medicine should be swallowed whole and avoid breaking or crushing.

If abnormal liver function or serious adverse reactions occur, the dose can be adjusted or the medication can be suspended under the guidance of a doctor.

The course of capmatinib treatment is generally continuous until disease progression or intolerable toxicity occurs. Liver function, blood routine and kidney function need to be monitored regularly during medication to ensure safety.

5. The efficacy advantages and limitations of capmatinib

1.Advantages:

Accurate and efficient: It has remarkable efficacy and high response rate for patients with MET mutations.

Fast onset of effect: Some patients' symptoms improve significantly within 2-3 weeks of taking the medicine.

Effective against brain metastasis:CNS has strong permeability and can control central lesions.

Well tolerated: most side effects are mild and manageable.

2.Limitations:

Only effective forMET mutation-positive patients;

Long-term medication costs are higher;

Individual patients may develop drug resistance and require subsequent adjustments to the regimen.

6. Domestic listing and medical insurance coverage

As of2025, capmatinib has been successfully approved for marketing in mainland China and has been officially included in the national medical insurance directory, becoming the first medical insurance targeted drug for patients with MET mutated lung cancer.

However, due to the short time on the market, hospitals and pharmacies in some areas have not yet fully distributed the drug. Patients may need to make an appointment in advance or order through oncology channels when purchasing the drug.

The current reimbursement rate for capmatinib by the national medical insurance can range from 50% to 70%, and the specific amount varies slightly according to local policies.

This progress in medical insurance has liberated many patients from the past "sky-high price medication" and greatly reduced their financial burden.

According to market information:

Domestic original drug price: Common packaging specifications of capmatinib are 200mg×56 tablets (approximately 28 daily dosage) or 100 mg In some regional pharmacies or specialty drug channels, the price may reach 3 million to 6 million.

Actual expenses after medical insurance reimbursement: The patient's out-of-pocket expenses range from approximately 8000 to 1.5 yuan.

Overseas original drug price: The selling price in European and American markets is usually per box4 10,000 to 100,000 yuan.

Price of generic drugs in Laos: Laos has launched a legally marketed generic drug of capmatinib. The ingredients of the drug are basically the same as the original drug. The price of 120 tablets is about 2000Multiple RMB is a great economic advantage for patients taking medicine for a long time.

However, patients need to be reminded that if they purchase through overseas channels, they should ensure that they choose formal certification channels to avoid purchasing counterfeit drugs or unapproved non-compliant drugs.

7. Feedback from real patients: stable efficacy and controllable side effects

Judging from the feedback from patients at home and abroad, capmatinib has excellent efficacy and tolerability.

After taking the medicine for some patients1 month, imaging showed that the tumor shrank significantly;

Symptoms such as dyspnea, cough, and chest pain were significantly relieved;

Headaches and neurological symptoms also improved in patients with brain metastases.

In terms of adverse reactions, common adverse reactions include mild peripheral edema, nausea, elevated transaminases, fatigue, etc. Most of them can be recovered after dose adjustment or symptomatic treatment.

Many patients said:“Capmatinib gives me hope again. It has no obvious side effects and I can live a normal life.” This also reflects the obvious comprehensive benefits of this drug in clinical application.

8. Future Prospects: From Lung Cancer to Precision Treatment of Multiple Cancers

The success of capmatinib not only lies in controlling RET mutated lung cancer, but also represents the clinical rise of MET signaling pathway inhibitors. Currently, researchers are exploring the potential application of capmatinib in the following diseases:

METAmplified gastric cancer and cholangiocarcinoma;

METMutation of kidney cancer and breast cancer;

Combined regimen with immunotherapy (PD-1 inhibitors).

With the release of more clinical data, capmatinib is expected to become one of the core drugs for precise targeted treatment of multiple cancer types.

The launch of capmatinib and its inclusion in medical insurance represent a new level of precision medicine in China. ForMETFor patients with mutated lung cancer, this is not only a drug, but also a life channel. In the future, with the improvement of drug accessibility, standardized production of generic drugs, and in-depth clinical research, capmatinib is expected to become an affordable and affordable "targeted hope" for more patients. As experts said: "The significance of targeted drugs is not only to prolong life, but also to allow patients to live with dignity."

xa0

References

1.GEOMETRY mono-1 Clinical Trial, New England Journal of Medicine, 2020.

2.NCCN Guidelines for NSCLC 2025 Update – https://www.nccn.org

3.Novartis Official Product Information – https://www.novartis.com

4.Announcement from the Center for Drug Evaluation of the State Food and Drug Administration of China (CDE)

5.ESMO 2024 Annual Report on MET Inhibitors